WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include pharmaceutical, biotechnology and medical device companies. The Company operates in two segments: laboratory services and manufacturing. Laboratory services for pharmaceutical, biotechnology and medical device companies. Manufacturing segment services for producing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials. In January 2008, the Company completed its acquisition of AppTec Laboratory Services, Inc.

Hoffmann-La Roche, Inc., also known as Roche, is a research-oriented pharmaceutical company. It provides medications in the areas of infectious diseases, metabolic diseases, neurology, oncology, transplantation and virology, AIDS, cardiovascular diseases, central nervous system disorders, and dermatology. Hoffmann-La Roche, Inc. was formerly known as Roche Chemical Works and changed its name to Hoffmann-La Roche Inc. in January 1929. The company was founded in 1905 and is headquartered in Nutley, New Jersey. It has research centers in Basel, Switzerland; Nutley, New Jersey; Penzberg, Germany; Shanghai, China; and Palo Alto, California. Hoffmann-La Roche, Inc. operates as a subsidiary of Roche Holding AG.

Peptimmune is pepped up about stopping the immune system when it malfunctions. The research-stage biotechnology company is focused on developing pharmaceuticals that treat medical conditions in which the body essentially attacks itself. Peptimmune conducts research and development programs on potential drug candidates targeting autoimmune and inflammatory ailments such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. The company partners with other pharmaceutical firms in some of its drug development efforts; it also relies on venture capital investors to help fund its research.

SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine.

ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

The Micron Group delves deeply into the world of drug discovery. Composed of companies based in the UK, the US, and South Africa -- including Micron Research, the group's flagship unit -- the group provides consulting services for pharmaceuticals research, development, and delivery companies. With expertise in Phase I-IV drug discovery trials, clinical research, data delivery, medical education, and medical communications, the group's services range from clinical development and research to marketing, strategic planning, and report publishing. The Micron Group also offers its SILK software for managing pharmaceutical R&D and marketing processes. Clients include Bristol-Myers Squibb and the World Health Organization.

Bioniche Life Sciences is seeking its niche in the development of drugs for both humans and animals. The firm has three divisions: Human Health, Animal Health, and Food Safety. The Bioniche Animal Health division sells products to improve livestock breeding and to boost livestock immunity without antibiotics. Bioniche's Food Safety division works to improve food and water quality by developing technology to prevent infections and diseases in animals that are passed on to humans. The company's Bioniche Therapeutics segment is developing pharmaceuticals to help humankind; it focuses on urology, oncology, and immune system disorders.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.